AgeX Therapeutics, Inc. announced that ImStem Biotechnology, Inc. has dosed the first US multiple sclerosis patient with ImStem’s lead investigational drug candidate IMS001.
[AgeX Therapeutics, Inc. (BusinessWire, Inc.)]
Sorry, but the selected Zotpress account can't be found.
